Summary of Key Points
Wang Xiaochuan is leading BaiChuan Intelligence to transition into the healthcare large-model sector. His understanding of the core aspects of medical AI—such as reasoning AI and reducing hallucinations—is precise and idealistic, but his strategy carries risks of over-optimism regarding external consumer markets (ToC) and misjudging the competitiveness of larger companies. To break through these challenges, the company should adopt a “2B2C” approach (leveraging hospitals/doctors as trusted partners to extend services to consumers) combined with external health services. The technology must respect the real-world rules of the healthcare industry in order to bridge the gap between technological leadership and commercial success.
I. Wang Xiaochuan’s Determination: Idealism and Insight Hit the Mark
Wang Xiaochuan’s choices and insights are commendable:
1. Accurate assessment of the core of medical AI: He believes that the next phase of medical AI is not about simply analyzing images (perception AI) but about analyzing conditions like a doctor would—using reasoning AI to ask questions like “How long have you had a fever? Do you have phlegm?” This addresses the current issue of AI making unfounded claims.
2. Choosing the most challenging yet valuable sector: While others are focusing on profitable areas like social media and search, he has chosen healthcare, stating that “by creating true doctors, AGI (Artificial General Intelligence) will follow.” His commitment to a difficult path integrates technology, vision, and business logic.
II. Strategic Doubts 1: Over-Optimism about External ToC Markets
Wang Xiaochuan thinks the external consumer market is the main battlefield, but there are two critical issues:
- Who bears the responsibility? Healthcare is not about selling products; it’s about saving lives. If AI makes a misdiagnosis, who should be held accountable—the AI company or the user? Chinese law has not yet clarified the liability in AI-related healthcare, so who would dare to let AI handle patients independently?
- User acceptance: Early online consultation models failed to make money because users were unwilling to pay and quickly stopped using them. For example, Babylon Health in the UK was once valued at $2 billion but went bankrupt due to patient safety controversies and lost hospital contracts. The direct-to-consumer approach does not work well in healthcare.
III. Strategic Doubts 2: Misjudging Competitiveness of Larger Companies
Wang Xiaochuan is concerned about companies like Alibaba, but they are not as strong in the healthcare sector:
Larger companies excel in standardization and scale (e.g., Alipay payments, Taobao recommendations), but healthcare is highly non-standardized. Each department and condition requires different approaches, and they often struggle with traditional hospital procedures (such as medical record-keeping) and compliance requirements (e.g., equipment certifications). Pure healthcare companies have the expertise that larger companies lack, which they cannot simply acquire through funding.
IV. The Way Forward: 2B2C + External Health Services
To be profitable in medical AI, a different approach is needed:
1. Adopt a 2B2C model: Collaborate with hospitals/doctors first; let AI serve as their assistant. For example, doctors can prescribe AI apps for patients to track their blood pressure at home, which the doctor can monitor remotely. This way, responsibility lies with the doctor (users trust doctors), and AI avoids risks while gaining user access through them.
2. Focus on external health services: Instead of focusing on diagnosing diseases (high risk, controlled by hospitals), focus on post-treatment care—e.g., nutrition monitoring for cancer patients, medication reminders for diabetics, sleep management for high-stress groups. These services are frequent, have a large margin for error, and hospitals often cannot handle them adequately. Policies also support this: Medical insurance now includes AI-assisted diagnosis, so hospitals are willing to invest in such tools.
The key is for AI to play the role of a helper for doctors and a companion for patients, leveraging its technical advantages while respecting healthcare industry norms.
Conclusion: The Sector Is Vast, but One Must Be Down-to-Earth
China’s AI healthcare market is expected to grow at a compound annual rate of 43% over the next decade, from 8.8 billion to 315.7 billion yuan—there is significant potential. However, no matter how advanced the technology, it cannot be applied in a rigid, internet-driven manner. Understanding the healthcare industry’s slow pace and responsibilities is essential. By allowing AI and doctors to complement each other, real commercial success can be achieved. Advanced technology will win the future only if it respects the reality of the healthcare sector.